London Regional Cancer Program, Canada
11
1
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
36.4%
4 terminated/withdrawn out of 11 trials
33.3%
-53.2% vs industry average
0%
0 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer
Role: collaborator
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Role: collaborator
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)
Role: collaborator
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.
Role: collaborator
A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
Role: collaborator
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II
Role: collaborator
Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*
Role: collaborator
Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
Role: collaborator
Dynamic Contrast Enhanced Computed Tomography (CT) for Head and Neck Cancer
Role: collaborator
Imaging Study of Glioblastomas Treated With Avastin
Role: collaborator
SPECT-CT Guided Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) in Prostate Cancer
Role: collaborator
All 11 trials loaded